CSL Limited is a global biotechnology company that develops, manufactures, and markets innovative biotherapies and vaccines to treat and prevent serious and life-threatening medical conditions. The company was founded in 1916 in Australia and currently has operations in over 30 countries.
CSL is divided into two main business segments: CSL Behring and Seqirus. CSL Behring produces biotherapeutics to treat rare and serious diseases including haemophilia, primary immune deficiencies, and neurological disorders. Seqirus focuses on the development and manufacturing of influenza vaccines.
CSL is dedicated to research and development and invests heavily in new therapies and manufacturing processes to improve patient outcomes, including gene therapies and precision medicine. The company is committed to ensuring access to its therapies for patients around the world.
CSL is listed on the Australian Securities Exchange and has a market capitalization of over $130 billion as of 2021. The company has won numerous awards for its innovation, sustainability, and commitment to social responsibility.
Ne Demek sitesindeki bilgiler kullanıcılar vasıtasıyla veya otomatik oluşturulmuştur. Buradaki bilgilerin doğru olduğu garanti edilmez. Düzeltilmesi gereken bilgi olduğunu düşünüyorsanız bizimle iletişime geçiniz. Her türlü görüş, destek ve önerileriniz için iletisim@nedemek.page